These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
5. Enhanced permeability and retention (EPR) effect for anticancer nanomedicine drug targeting. Greish K Methods Mol Biol; 2010; 624():25-37. PubMed ID: 20217587 [TBL] [Abstract][Full Text] [Related]
6. Nucleoside analogue delivery systems in cancer therapy. Diab R; Degobert G; Hamoudeh M; Dumontet C; Fessi H Expert Opin Drug Deliv; 2007 Sep; 4(5):513-31. PubMed ID: 17880274 [TBL] [Abstract][Full Text] [Related]
7. Polymeric nano-micelles: versatile platform for targeted delivery in cancer. Mohamed S; Parayath NN; Taurin S; Greish K Ther Deliv; 2014 Oct; 5(10):1101-21. PubMed ID: 25418269 [TBL] [Abstract][Full Text] [Related]
8. Current Approaches for Improving Intratumoral Accumulation and Distribution of Nanomedicines. Durymanov MO; Rosenkranz AA; Sobolev AS Theranostics; 2015; 5(9):1007-20. PubMed ID: 26155316 [TBL] [Abstract][Full Text] [Related]
9. Nanoparticles for delivery of chemotherapeutic agents to tumors. Vijayaraghavalu S; Raghavan D; Labhasetwar V Curr Opin Investig Drugs; 2007 Jun; 8(6):477-84. PubMed ID: 17621878 [TBL] [Abstract][Full Text] [Related]
10. Immunomodulation of hematological malignancies using oligonucleotides based-nanomedicines. Hazan-Halevy I; Landesman-Milo D; Rosenblum D; Mizrahy S; Ng BD; Peer D J Control Release; 2016 Dec; 244(Pt B):149-156. PubMed ID: 27491881 [TBL] [Abstract][Full Text] [Related]
11. Polymeric drugs for efficient tumor-targeted drug delivery based on EPR-effect. Maeda H; Bharate GY; Daruwalla J Eur J Pharm Biopharm; 2009 Mar; 71(3):409-19. PubMed ID: 19070661 [TBL] [Abstract][Full Text] [Related]
12. Engineered nanoparticles for drug delivery in cancer therapy. Sun T; Zhang YS; Pang B; Hyun DC; Yang M; Xia Y Angew Chem Int Ed Engl; 2014 Nov; 53(46):12320-64. PubMed ID: 25294565 [TBL] [Abstract][Full Text] [Related]
13. Challenges, expectations and limits for nanoparticles-based therapeutics in cancer: a focus on nano-albumin-bound drugs. Fanciullino R; Ciccolini J; Milano G Crit Rev Oncol Hematol; 2013 Dec; 88(3):504-13. PubMed ID: 23871532 [TBL] [Abstract][Full Text] [Related]
14. Role of integrated cancer nanomedicine in overcoming drug resistance. Iyer AK; Singh A; Ganta S; Amiji MM Adv Drug Deliv Rev; 2013 Nov; 65(13-14):1784-802. PubMed ID: 23880506 [TBL] [Abstract][Full Text] [Related]
15. Emerging nanomedicines for early cancer detection and improved treatment: current perspective and future promise. Bharali DJ; Mousa SA Pharmacol Ther; 2010 Nov; 128(2):324-35. PubMed ID: 20705093 [TBL] [Abstract][Full Text] [Related]
16. Investigational antibody-drug conjugates for hematological malignancies. Polson AG; Ho WY; Ramakrishnan V Expert Opin Investig Drugs; 2011 Jan; 20(1):75-85. PubMed ID: 21142808 [TBL] [Abstract][Full Text] [Related]
17. Biodegradable, polymeric nanoparticle delivery systems for cancer therapy. Pridgen EM; Langer R; Farokhzad OC Nanomedicine (Lond); 2007 Oct; 2(5):669-80. PubMed ID: 17976029 [TBL] [Abstract][Full Text] [Related]
18. Nanodrugs used in cancer therapy. Kopeckova K; Eckschlager T; Sirc J; Hobzova R; Plch J; Hrabeta J; Michalek J Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub; 2019 Jun; 163(2):122-131. PubMed ID: 30967685 [TBL] [Abstract][Full Text] [Related]
19. Anticancer nanomedicine and tumor vascular permeability; Where is the missing link? Taurin S; Nehoff H; Greish K J Control Release; 2012 Dec; 164(3):265-75. PubMed ID: 22800576 [TBL] [Abstract][Full Text] [Related]